


**Foundations of Cardiometabolic Health Certification Course** 

**Certified Cardiometabolic Health Professional (CCHP)** 



•	NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis	9
•	2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients with Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee	(1)
•	Hypertriglyceridemia Management According to the 2018 AHA/ACC Guideline	(
•	Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factors for Atherosclerotic Cardiovascular Disease: A Scientific Statement from the American Heart Association	(
111	portant Suggested Readings and Resources:	
•	A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies	(4
		(4
•	A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies	(
•	A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies  The dedicated "Lp(a) clinic": A concept whose time has arrived?	
•	A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies  The dedicated "Lp(a) clinic": A concept whose time has arrived?  Emerging RNA Therapeutics to Lower Blood Levels of Lp(a): JACC Focus Seminar 2/4	(-)
•	A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies  The dedicated "Lp(a) clinic": A concept whose time has arrived?  Emerging RNA Therapeutics to Lower Blood Levels of Lp(a): JACC Focus Seminar 2/4  Statin therapy increases lipoprotein(a) levels	(